Back to Search Start Over

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Authors :
Schmidt, Amand F.
Swerdlow, Daniel I
Holmes, Michael V
Patel, Riyaz S.
Fairhurst-Hunter, Zammy
Lyall, Donald M
Hartwig, Fernando Pires
Horta, Bernardo Lessa
Hyppönen, Elina
Power, Christine
Moldovan, Max
van Iperen, Erik Pa
Hovingh, G. Kees
Demuth, Ilja
Norman, Kristina
Steinhagen-Thiessen, Elisabeth
Demuth, Juri
Bertram, Lars
Liu, Tian
Coassin, Stefan
Willeit, Johann
Kiechl, Stefan
Willeit, Karin
Mason, Dan
Wright, John
Morris, Richard W
Wanamethee, Goya
Whincup, Peter H
Ben-Shlomo, Yoav
McLachlan, Stela
Price, Jackie F
Kivimaki, Mika
Welch, Catherine
Sanchez-Galvez, Adelaida
Marques-Vidal, Pedro
Nicolaides, Andrew N.
Panayiotou, Andrie G.
Onland-Moret, N Charlotte
van der Schouw, Yvonne T
Matullo, Giuseppe
Fiorito, Giovanni
Guarrera, Simonetta
Sacerdote, Carlotta
Wareham, Nicholas J.
Langenberg, Claudia
Scott, Robert A
Luan, Jian'an
Smith, Daniel J
Maitland-van der Zee, Anke H
Baranova, Ekaterina V
LifeLines Cohort Study Group
Schmidt, Amand F.
Swerdlow, Daniel I
Holmes, Michael V
Patel, Riyaz S.
Fairhurst-Hunter, Zammy
Lyall, Donald M
Hartwig, Fernando Pires
Horta, Bernardo Lessa
Hyppönen, Elina
Power, Christine
Moldovan, Max
van Iperen, Erik Pa
Hovingh, G. Kees
Demuth, Ilja
Norman, Kristina
Steinhagen-Thiessen, Elisabeth
Demuth, Juri
Bertram, Lars
Liu, Tian
Coassin, Stefan
Willeit, Johann
Kiechl, Stefan
Willeit, Karin
Mason, Dan
Wright, John
Morris, Richard W
Wanamethee, Goya
Whincup, Peter H
Ben-Shlomo, Yoav
McLachlan, Stela
Price, Jackie F
Kivimaki, Mika
Welch, Catherine
Sanchez-Galvez, Adelaida
Marques-Vidal, Pedro
Nicolaides, Andrew N.
Panayiotou, Andrie G.
Onland-Moret, N Charlotte
van der Schouw, Yvonne T
Matullo, Giuseppe
Fiorito, Giovanni
Guarrera, Simonetta
Sacerdote, Carlotta
Wareham, Nicholas J.
Langenberg, Claudia
Scott, Robert A
Luan, Jian'an
Smith, Daniel J
Maitland-van der Zee, Anke H
Baranova, Ekaterina V
LifeLines Cohort Study Group
Source :
The Lancet Diabetes and Endocrinology vol.5 (2017) nr.2 p.97-105 [ISSN 2213-8587]
Publication Year :
2017

Abstract

BACKGROUND: Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol-lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk.METHODS: In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores.FINDINGS: Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c(0·03%, -0·01 to 0·08), fasting insulin (0·00%, -0·06 to 0·07), and BMI (0·11 kg/m2, -0·09 to 0·30).INTERPRETATION: PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits

Details

Database :
OAIster
Journal :
The Lancet Diabetes and Endocrinology vol.5 (2017) nr.2 p.97-105 [ISSN 2213-8587]
Notes :
DOI: 10.1016/S2213-8587(16)30396-5, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1445803840
Document Type :
Electronic Resource